2026 Open Call for grants - Impact Grants

Impact Grant Program is sponsored by The Supporting Act Foundation. The Supporting Act Foundation Impact Grant provides unrestricted funding to arts-focused nonprofit organizations that support emerging artists from underrepresented groups and communities facing systemic barriers in the creative and cultural industries. The grant allows organizations to invest in core needs like salaries and infrastructure. In 2026, 10 organizations will receive these grants.

The Merck Stimulating Innovative Research Grant Program 2026 includes a dedicated grant topic for artificial intelligence in cell culture media and process development, offering up to EUR 150,000 per year for up to 3 years. The program accelerates innovation through collaborative research, early engagement with industry experts, and translation of novel ideas into practical solutions. In 2026, priority areas also include in-vitro models for neuroinflammatory diseases (EUR 250,000/year for 2 years) and innovative approaches to contaminated materials remediation (EUR 150,000/year for 2 years). The two-stage application process begins with non-confidential submissions, followed by deep-dive workshops where finalists collaborate with Merck scientists and managers to jointly optimize proposals. The AI-specific grant focuses on applying machine learning and AI to optimize cell culture media formulation, bioprocess parameter optimization, and manufacturing quality control.

Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.